Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 3)

Link copied
Case Copied 8 min read

FEDERAL COURT OF AUSTRALIA

Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC (No 3)

[2006] FCA 1797  

RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826) v WARNER-LAMBERT COMPANY LLC AND COMMISSIONER OF PATENTS
VID 926 OF 2005

YOUNG J
20 DECEMBER 2006
MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 926 OF 2005

BETWEEN:

RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Applicant/Cross-Respondent

AND:

WARNER-LAMBERT COMPANY LLC
First Respondent/Cross-Claimant

COMMISSIONER OF PATENTS
Second Respondent

JUDGE:

YOUNG J

DATE OF ORDER:

20 DECEMBER 2006

WHERE MADE:

MELBOURNE

THE COURT FURTHER ORDERS THAT:

3.Order 1 of the orders made by the Court this day be stayed until:

(a)Friday 9 February 2007; or

(b)if an appeal from these orders is lodged on or before Friday 9 February 2007, the determination of that appeal or further order.

4.The time for filing any notice of appeal be extended to 9 February 2007.

5.The applicant/cross-respondent pay the first respondent/cross-claimant’s costs of and incidental to the cross claim.

6.The first respondent/cross-claimant pay to the applicant/cross-respondent 60 per cent of the applicant/cross-respondent’s costs of and incidental to the amended application, including the costs of and incidental to the notice of motion dated 24 May 2006.

7.The applicant/cross-respondent pay the first respondent/cross-claimant’s costs of and incidental to the notices of motion dated 20 October 2005 and 18 April 2006.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 926 OF 2005

BETWEEN:

RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Applicant/Cross-Respondent

AND:

WARNER-LAMBERT COMPANY LLC
First Respondent/Cross-Claimant

COMMISSIONER OF PATENTS
Second Respondent

JUDGE:

YOUNG J

DATE:

20 DECEMBER 2006

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. The effect of my decision in Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 2) [2006] FCA 1787 (‘Ranbaxy (No 2)’) is that the applicant/cross-respondent, Ranbaxy Australia Pty Ltd (‘Ranbaxy’), has obtained the relief it sought by its amended application, and the first respondent/cross-claimant, Warner-Lambert Company LLC (‘Warner Lambert’) has obtained the primary relief it sought by its cross claim.  After I delivered judgment, I invited the parties to make submissions on the issue of costs and other orders.

    COSTS

  2. The general principles governing the question of costs are not in doubt: see Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 at 497-498 [10]; and Koninklijke Philips Electronics NV v Remington Products Australia Pty Ltd (1999) 45 IPR 634 at 639 [17]. In the absence of special circumstances, the ordinary rule is that the costs of each claim should respectively follow the event of each claim.

  3. Ranbaxy accepts that the ordinary rule should apply to Warner-Lambert’s cross claim in respect of which I have made an injunctive order.  Accordingly, I will order that Ranbaxy pay Warner-Lambert’s costs of and incidental to Warner-Lambert’s cross claim. 

  4. With regard to Ranbaxy’s amended application, Ranbaxy concedes that there are special circumstances that warrant a departure from the ordinary rule…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 3) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] FCA 1797
Decision Date

CaseChat Overview and Summary

Ranbaxy Australia Pty Ltd sought revocation of Australian Letters Patent No 628198 (the Enantiomer Patent) and Warner-Lambert Company LLC cross-claimed for an injunction. The case involved patent law, specifically the validity of the Enantiomer Patent and potential patent infringement by Ranbaxy’s product. The Federal Court of Australia, under Justice Young, was tasked with determining the costs and other orders following the decision in Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC (No 2). The court had to decide whether the costs incurred by Ranbaxy should follow the event, considering the special circumstances of the case. Additionally, the court needed to determine the costs related to several notices of motion and the admissibility of certain affidavit evidence.

Justice Young concluded that the ordinary rule of costs should apply, with Ranbaxy paying Warner-Lambert’s costs for the cross claim. Regarding Ranbaxy’s amended application, Justice Young found special circumstances warranted a departure from the ordinary rule. Ranbaxy had abandoned three grounds of invalidity shortly before the trial, leading to wasted costs. However, Justice Young determined that Ranbaxy’s costs should be reduced by 40% rather than ordering Warner-Lambert to pay Ranbaxy’s costs. Warner-Lambert was awarded the costs of two notices of motion, while Ranbaxy was to bear the costs of the third, given the lack of practical success. The court also made orders to stay the revocation of the Enantiomer Patent pending appeal and to extend the time for filing an appeal notice.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

YOUNG J

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Established by: YOUNG J

Full text does not contain this section.